摘要
目的:了解江苏省医药制造业产业集群水平的发展情况,为其进一步发展提供建议。方法:从波特"钻石模型"4个关键要素(生产要素、需求条件、结构和同业竞争、相关与支持性产业和企业战略)的角度,构建医药制造业产业集群水平评价指标体系,并运用主成分分析(PCA)法对江苏省2000-2012年医药制造业产业集群水平的发展情况进行实证研究。结果与结论:从整体来看,江苏省医药制造业产业集群水平综合得分从2000年的0.140 7上升到2012年的0.176 8。从3个主成分得分来看,反映产业规模与经济效益的第1个主成分从0.208 8逐步上升到0.291 9;反映产业竞争能力的第3个主成分从0.025 3逐步上升到0.071 2,二者总体呈上升趋势;反映产业增值盈利能力及相关机构支撑力度的第2个主成分先从2000年的0.161 6上升到2005年的0.242 3,然后开始逐渐下降,至2012年仅为0.131 5,呈现先升后降的趋势。这表明江苏省医药制造业的产业规模和经济效益发展形势良好,产业的竞争能力逐步增强,但产业的增值盈利能力以及相关机构的支撑力度还有待改善。建议进一步加大产业规模和增强经济效益,提升产业增值盈利能力,改善相关机构的支撑力度,并增强产业的竞争能力,以促进江苏省医药制造业产业集群的合理发展。
OBJECTIVE： To investigate the development of pharmaceutical manufacturing industrial cluster in Jiangsu province as well as to put forward some suggestions for further development. METHODS： In empirical study, the development of pharma- ceutical manufacturing industrial cluster in Jiangsu province from 2000 to 2012 was studied by the method of principal component analysis （PCA） based on the assessment indexes system of the pharmaceutical manufacturing industrial cluster, from the perspec- tive of 4 key elements of Porter diamond model （production factors, demand condition, structure and competition, related support- ing industries and enterprise strategy）. RESULTS ＆ CONCLUSIONS： The synthesis score of cluster level of pharmaceutical manu- facturing industry went up from 0.140 7 in 2000 to 0.176 8 in 2012. According to 3 principal component scores, the first and third principal components were in a rising trend as the first reflecting the industry scale and economic benefits gradually went up from 0.208 8 to 0.291 9, and the third reflecting the industry competitiveness went up from 0.025 3 to 0.071 2. The second principal com- ponent tended to increase first and then decrease, decreasing to 0.131 5 in 2012 after having increased from 0.161 6 in 2000 to 0.242.3 in 2005, which reflected the industrial value-added profit ability and relevant institution support. This indicated that the in- dustry scale, economic benefits and industrial competitiveness were well-developed, but industrial value-added profit ability and rel- evant institutions support yet need to be improved. It is suggested to further expand and enhance the industry scale and economic benefit of pharmaceutical manufacturing industry, improve industrial value-added profit ability and the relevant institutions support, and strengthen industrial competitiveness so as to promote rational development of pharmaceutical manufacturing industrial cluster in Jian^su province.
出处
《中国药房》
CAS
北大核心
2015年第7期868-871,共4页
China Pharmacy
关键词
江苏省
医药制造业
产业集群
主成分分析法
Jiangsu province
Pharmaceutical manufacturing industry
Industrial cluster
Principal component analysis
